You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Enhanced hepatoprotection and bioavailability of silybin by coamorphous silybin-ursodeoxycholic acid
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-B-097-Tuesday
- By: LIU, Dongchun (Shenyang Pharmaceutical University, department of Traditional Chinese Medicine, shenyang, China)
- Co-author(s): Dongchun Liu: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
Xiafei Shi: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
Fang Wang: Faculty of functional food and wine, Shenyang Pharmaceutical University, Shenyang, China
Huan Chen: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
Dong Wang: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
Yinghui Dai: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
Xing Tang: Faculty of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China - Abstract:
Backgrounds
Silybin (SLB), an antihepatopathy flavonolignan derived from the herb milk thistle (Silybum marianum), is poorly soluble and exists in form of microcrystals,resulting in poor oral bioavailability. Ursodeoxycholic acid (UDCA), a kind of hydrophilic bile acid, is most widely used for the treatment of cholestatic hepatopathies. Combined.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026